BR112019004276A2 - métodos para o tratamento de câncer ovariano - Google Patents

métodos para o tratamento de câncer ovariano

Info

Publication number
BR112019004276A2
BR112019004276A2 BR112019004276A BR112019004276A BR112019004276A2 BR 112019004276 A2 BR112019004276 A2 BR 112019004276A2 BR 112019004276 A BR112019004276 A BR 112019004276A BR 112019004276 A BR112019004276 A BR 112019004276A BR 112019004276 A2 BR112019004276 A2 BR 112019004276A2
Authority
BR
Brazil
Prior art keywords
ovarian cancer
methods
treating ovarian
treating
revealed
Prior art date
Application number
BR112019004276A
Other languages
English (en)
Inventor
Hattersley Gary
Original Assignee
Radius Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Radius Health Inc filed Critical Radius Health Inc
Publication of BR112019004276A2 publication Critical patent/BR112019004276A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

revelados são métodos de tratamento de câncer ovariano.
BR112019004276A 2016-09-27 2017-09-27 métodos para o tratamento de câncer ovariano BR112019004276A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662400495P 2016-09-27 2016-09-27
PCT/US2017/053834 WO2018064231A1 (en) 2016-09-27 2017-09-27 Methods for treating ovarian cancer

Publications (1)

Publication Number Publication Date
BR112019004276A2 true BR112019004276A2 (pt) 2019-06-04

Family

ID=61760096

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019004276A BR112019004276A2 (pt) 2016-09-27 2017-09-27 métodos para o tratamento de câncer ovariano

Country Status (21)

Country Link
US (2) US20200009085A1 (pt)
EP (1) EP3518911B1 (pt)
JP (1) JP2019532934A (pt)
KR (2) KR20190058568A (pt)
CN (1) CN109715149A (pt)
AU (1) AU2017336564A1 (pt)
BR (1) BR112019004276A2 (pt)
CA (1) CA3036568A1 (pt)
CY (1) CY1125266T1 (pt)
ES (1) ES2898072T3 (pt)
HR (1) HRP20211804T1 (pt)
HU (1) HUE057064T2 (pt)
IL (1) IL265537B2 (pt)
LT (1) LT3518911T (pt)
MX (1) MX2019003311A (pt)
PL (1) PL3518911T3 (pt)
PT (1) PT3518911T (pt)
RS (1) RS62660B1 (pt)
SG (2) SG11201901759XA (pt)
SI (1) SI3518911T1 (pt)
WO (1) WO2018064231A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020311337A1 (en) * 2019-07-07 2022-01-20 Olema Pharmaceuticals, Inc. Regimens of estrogen receptor antagonists

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010044431A1 (en) * 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
CN1927815A (zh) * 2006-09-25 2007-03-14 天津理工大学 邻苄胺基苯基醚化合物、化合物的衍生物及其制备方法与用途
US20110009387A1 (en) * 2007-06-12 2011-01-13 Andrea Dawn Basso-Porcaro Histone h2ax (hh2ax) biomarker for fti sensitivity
GB201217439D0 (en) * 2012-09-28 2012-11-14 Topotarget As Combination therapy
CA2915534A1 (en) * 2013-06-19 2014-12-24 Seragon Pharmaceuticals, Inc. Azetidine estrogen receptor modulators and uses thereof
CN104436194B (zh) * 2013-09-18 2018-03-30 北京大学 具有协同增效作用的抗癌组合物
EP3116497A2 (en) * 2014-03-13 2017-01-18 F. Hoffmann-La Roche AG Therapeutic combinations with estrogen receptor modulators
US9421264B2 (en) * 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
US9980947B2 (en) * 2014-12-18 2018-05-29 Genentech, Inc. Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof
CN105848374A (zh) * 2015-01-12 2016-08-10 芋头科技（杭州）有限公司 一种灯光控制系统及方法
CA2973373C (en) * 2015-01-28 2023-08-01 Corex, Llc Battery enclosure for sterilizeable surgical tools having thermal insulation
IL297369B1 (en) * 2015-04-29 2024-02-01 Radius Pharmaceuticals Inc RAD for use in a method to treat mutant estrogen receptor positive breast cancer or mutant estrogen receptor positive ovarian cancer

Also Published As

Publication number Publication date
EP3518911A1 (en) 2019-08-07
RU2019108382A (ru) 2020-10-29
JP2019532934A (ja) 2019-11-14
SG10202104282SA (en) 2021-06-29
ES2898072T3 (es) 2022-03-03
HRP20211804T1 (hr) 2022-02-18
CN109715149A (zh) 2019-05-03
IL265537B (en) 2022-12-01
EP3518911A4 (en) 2020-05-13
CY1125266T1 (el) 2023-03-24
SG11201901759XA (en) 2019-04-29
KR20230152814A (ko) 2023-11-03
MX2019003311A (es) 2019-07-08
RS62660B1 (sr) 2021-12-31
SI3518911T1 (sl) 2022-02-28
RU2019108382A3 (pt) 2020-12-28
WO2018064231A1 (en) 2018-04-05
CA3036568A1 (en) 2018-04-05
AU2017336564A1 (en) 2019-03-14
PL3518911T3 (pl) 2022-02-07
LT3518911T (lt) 2021-12-10
EP3518911B1 (en) 2021-08-25
IL265537A (en) 2019-05-30
PT3518911T (pt) 2021-11-11
HUE057064T2 (hu) 2022-04-28
US20200009085A1 (en) 2020-01-09
IL265537B2 (en) 2023-04-01
KR20190058568A (ko) 2019-05-29
US20230129787A1 (en) 2023-04-27

Similar Documents

Publication Publication Date Title
BR112017023821A2 (pt) moduladores de k-ras
MX2019007030A (es) Composiciones y metodos para el tratamiento del cancer.
CL2018003123A1 (es) Terapia de combinación para el tratamiento del cáncer
DK3478286T3 (da) Fremgangsmåder til behandling af ovariecancer
DK3580211T3 (da) 2-heteroaryl-3-oxo-2,3-dihydropyridazin-4-carboxamider til behandling af cancer
IL263497B (en) 1-tetrahydropyranylcarbonyl-3,2-dihydro-h1-indole compounds for cancer treatment
BR112017007170A2 (pt) anticorpos anti-ox40 humanizados e suas utilizações
BR112018003269A2 (pt) conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização
EA201990296A1 (ru) Антитела против siglec-7 для лечения рака
EA201991818A1 (ru) Лечение рака
EP3405203A4 (en) METHODS OF TREATING CANCER
EP3440112A4 (en) METHOD FOR THE TREATMENT OF CANCER
BR112018000776A2 (pt) métodos para tratamento de câncer usando apilimod
PH12017501879A1 (en) Methods for treating cancer
CY1123019T1 (el) Σπειροκυκλικες ενωσεις
BR112018005331A2 (pt) inibidores de pcna
JO3541B1 (ar) علاجات طبية قائمة على اناموريلين
EA201691896A1 (ru) Соединения и способы их применения
DK3407909T3 (da) Cancerbehandling
CY1125266T1 (el) To rad1901 για χρηση στη θεραπεια του καρκινου των ωοθηκων
EP3597197A4 (en) NEW TECHNOLOGY FOR TREATMENT OF CANCER USING STRUCTURALLY REINFORCED S-TUD
AU2016902922A0 (en) Methods of Treating Cancer (I)

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B25A Requested transfer of rights approved

Owner name: RADIUS PHARMACEUTICALS, INC. (US)

B25G Requested change of headquarter approved

Owner name: RADIUS PHARMACEUTICALS, INC. (US)

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]